# Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

> **NCT03123588** · PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 12 (actual)

## Conditions studied

- MPN (Myeloproliferative Neoplasms)

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Anagrelide
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03123588
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-14
- **Primary completion:** 2020-08-03
- **Final completion:** 2020-08-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Enrollment issues
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123588, "Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03123588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*